

COMPANY OVERVIEW

Citius Pharmaceuticals (NASDAQ: CTXR) is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for large and growing markets. Citius is currently advancing two proprietary product candidates, our Mino-Lok™ product and a hydrocortisone-lidocaine formulation. Citius believes the markets for its products are large and underserved by the current standard of care.

RECENT NEWS

Citius Pharmaceuticals' Mino-Lok® Highly Efficacious in Rapidly Eradicating Candida auris

May 13 2019, 8:47 AM EDT

Citius Pharmaceuticals to Present at the ThinkEquity Conference

May 1 2019, 8:00 AM EDT

Citius Pharmaceuticals Presents Data on Mino-Lok® Showing 98% Clinical Efficacy

Apr 30 2019, 9:45 AM EDT

STOCK OVERVIEW

Symbol	CTXR
Exchange	Nasdaq
Market Cap	30.46m
Last Price	\$1.38
52-Week Range	\$0.8582 - \$3.15

05/17/2019 04:00 PM EDT

INVESTOR RELATIONS

Andrew Scott
VP of Investor Relations
T: 908-967-6677 ext. 105

MANAGEMENT TEAM

Myron Holubiak

President, Chief Executive Officer and Director

Jaime Bartushak

Chief Financial Officer and Principal Financial Officer

Gary F. Talarico

Executive Vice President, Operations

CITIUS PHARMACEUTICALS, INC.

11 Commerce Drive, First Floor
Cranford, NJ 07016
US

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.